Synta PharmaceuticalsAnnounces STA-9090 Results Demonstrating Potent In vitro and In vivo Activity in AML 2/8/2010
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Provides Update on Meeting With FDA to Discuss Pivotal Study Design for Sapacitabine 12/15/2009
More...
|
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 12/11/2009
More...
|
Cyclacel Limited (CYCC) Reports Phase 2 Sapacitabine Data in Acute Myeloid Leukemia and Myelodysplastic Syndromes at 2009 American Society of Hematology Annual Meeting 12/7/2009
More...
|
OXiGENE (OXGN) Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at American Society of Hematology Conference 12/7/2009
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia 10/29/2009
More...
|
EpiCept Corporation (EPCT) Release: New Data Supports Pharmacoeconomic Benefits of Ceplene(R) 10/26/2009
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Phase 2 Sapacitabine Data in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes At 2009 American Society of Clinical Oncology Annual Meeting 5/29/2009
More...
|
Lorus Therapeutics Inc. (LRP) Announces Presentation of New Supportive Data for LOR-2040 in Acute Myeloid Leukemia 4/22/2009
More...
|
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia 12/9/2008
More...
|
Myelodysplastic Syndromes (MDS) Foundation Release: Data Presented at this Year’s ASH Meeting Demonstrate Prolonged Overall Survival for Patients with Acute Myeloid Leukemia 12/9/2008
More...
|
Antisoma PLC (ASM.L) Announces Positive Interim Data From AS1411 Phase II Trial In Acute Myeloid Leukaemia 12/8/2008
More...
|
EpiCept Corporation (EPCT) Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival 6/12/2008
More...
|
Preliminary Analyses from Phase 2 Genzyme Corporation (GENZ) Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients Data Show Encouraging Results for a Potential New Front-Line Treatment Approach in AML 6/3/2008
More...
|
Vion Pharmaceuticals (VION) Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting 6/3/2008
More...
|
Vion Pharmaceuticals (VION) Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting 6/2/2008
More...
|
Xanthus Pharmaceuticals, Inc. Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML 6/2/2008
More...
|
EpiCept Corporation (EPCT) Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe 5/27/2008
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC)’s Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators 5/27/2008
More...
|
Warnex Inc. (CC:WNX) Obtains Licence From Xenomics Inc. (XNOM) for Acute Myeloid Leukemia Test 2/28/2008
More...
|
MethylGene and Pharmion Corporation (PHRM) Announce Orphan Drug Designation Granted by the European Medicines Evaluation Agency for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2/11/2008
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Initiates Phase 2 Sapacitabine Trial in Elderly AML Patients 1/2/2008
More...
|
Oregon Health & Science University (OHSU) Cancer Institute Researchers Help Develops Test For Targeted Therapy In Acute Myeloid Leukemia 12/11/2007
More...
|
Antisoma PLC (ASM.L) Presentation Supports Antisoma PLC (ASM.L)'s Phase II Trial in AML 12/10/2007
More...
|
Xanthus Pharmaceuticals, Inc.' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute Myeloid Leukemia 12/10/2007
More...
|
Avalon Pharmaceuticals (AVRX): AVN944 Biomarkers Correlate with Clinical Effects and Disease Stabilization in Adult AML Patients 12/10/2007
More...
|
Ambit Biosciences Presents Data on AC220 in Acute Myeloid Leukemia at American Society of Hematology Conference 12/10/2007
More...
|
ImmunoGen, Inc. (IMGN) Announces Encouraging Clinical Findings Reported at American Society of Hematology Annual Meeting for TAP Compound AVE9633 12/10/2007
More...
|
Seattle Genetics, Inc. (SGEN) Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at American Society of Hematology 12/10/2007
More...
|
Seattle Genetics, Inc. (SGEN) Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia 11/9/2007
More...
|
European Commission Grants Orphan Drug Designation to Xanthus Pharmaceuticals, Inc.'s Xanafide for the Treatment of Acute Myeloid Leukemia 10/26/2007
More...
|
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia 10/15/2007
More...
|
Xanthus Pharmaceuticals, Inc. Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia 10/8/2007
More...
|
ChemGenex Pharmaceuticals Limited (CXS.AX) Announces Second Publication Demonstrating Activity of Ceflatonin(R) in T315I-Positive Chronic Myeloid Leukemia (CML) 9/24/2007
More...
|
Xanthus Pharmaceuticals, Inc.'s Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells 9/13/2007
More...
|
Antisoma PLC (ASM.L) Starts Phase II Trial of AS1411 in Acute Myeloid Leukaemia 8/6/2007
More...
|
INNOVIVE Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Phase II Clinical Trial with Tamibarotene in Refractory Acute Promyelocytic Leukemia 8/3/2007
More...
|
Geron Corporation (GERN) Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia 7/11/2007
More...
|
Xanthus Pharmaceuticals, Inc. Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia 6/12/2007
More...
|
Umbilical Cord Best Treatment for Childhood Leukaemia 6/8/2007
More...
|
MGI PHARMA, INC. (MOGN) Summarizes Data Presented at the 2007 American Society of Clinical Oncology Annual Meeting 6/5/2007
More...
|
Xanthus Pharmaceuticals, Inc. Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML 6/4/2007
More...
|
Generex Biotechnology Corporation (GNBT) Vaccine Development Programs Presented at the Annual Meeting of the American Association for Cancer Research 4/16/2007
More...
|
Ambit Biosciences Begins Dosing Patients in Phase I Clinical Trial of Lead Kinase Inhibitor AC220 4/10/2007
More...
|
Vion Pharmaceuticals (VION) Extends Agreement With SAFC Pharma Partnership for Cloretazine(R) (VNP40101M) API Manufacturing 3/22/2007
More...
|
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down 3/1/2007
More...
|
Bioenvision (BIVN) Files With EMeA For Label Extension Of Evoltra(R) 2/7/2007
More...
|
Researchers Develop New Strategy For The Treatment Of CML 1/18/2007
More...
|
Role For Proteomics In Identifying Hematologic Malignancies 1/11/2007
More...
|
Xanthus Pharmaceuticals, Inc. Receives Orphan Drug Designation Of Xanafide For The Treatment Of AML 1/8/2007
More...
|
MGI PHARMA, INC. (MOGN) Release: Dacogen(TM) (Decitabine) For Injection Data Presented At The American Society of Hematology (ASH) 48th Annual Meeting And Exposition 12/12/2006
More...
|
Xanthus Pharmaceuticals, Inc. Completes Enrollment Of Phase 2 Trial Of Xanafide For The Treatment Of Secondary AML 12/4/2006
More...
|
Study Identifies Molecular Process Underlying Leukemia 8/22/2006
More...
|
Lorus Therapeutics Inc. (LRP) Announces New Clinical Program With GTI-2040 In Myelodysplastic Syndrome And Acute Myeloid Leukemia 6/19/2006
More...
|
Xenomics Inc. (XNOM) Enters Tumor Diagnostics Area By Licensing DNA Marker For Acute Myeloid Leukemia (AML) 6/7/2006
More...
|
CuraGen Corporation (CRGN) And TopoTarget A/S Announce Initiation Of National Cancer Institute-Sponsored Phase II Clinical Trial With PXD101 For Acute Myelogenous Leukemia 6/6/2006
More...
|
Novartis Corporation (NVS) Release: Gleevec(R) Sets New Treatment Standard In Chronic Myeloid Leukemia With High Overall Survival, Increasing Response And Decreasing Progression 6/5/2006
More...
|
Xanthus Pharmaceuticals, Inc. Meets Milestone In Phase 2 Clinical Study Of Xanafide For Treatment Of Secondary AML 6/5/2006
More...
|
Cell Genesys, Inc. (CEGE) Reports Long-Term Follow-Up Data From Phase 2 Trial Of GVAX(R) Immunotherapy For Leukemia In Chronic Myelogenous Leukemia 6/5/2006
More...
|
Lorus Therapeutics Inc. (LRP) Announces Presentation Of Data From Four Clinical Trials With Three Different Drugs At The 2006 American Society of Clinical Oncology Meeting 6/1/2006
More...
|
Vion Pharmaceuticals (VION) Initiates Pivotal Phase II Trial Of Single Agent Cloretazine(R) In Elderly Patients With De Novo Poor-Risk Acute Myelogenous Leukemia 5/24/2006
More...
|
Genzyme Corporation (GENZ) Releases Two New Molecular Tests For Acute Myelogenous Leukemia 5/17/2006
More...
|
Cephalon, Inc. (CEPH) Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation For Acute Myeloid Leukemia 4/4/2006
More...
|
Vion Pharmaceuticals (VION) Presents Preclinical Data On Cloretazine(R) (VNP40101M), A Hypoxia-Selective Compound (VNP40541) And Hydrazones At American Association for Cancer Research Meeting 4/4/2006
More...
|
EpiCept Corporation Announces Publication Of Phase III Ceplene(TM) Study Results For Acute Myeloid Leukemia 3/31/2006
More...
|
ChemGenex Pharmaceuticals Limited (CXS.AX) Release: New Preclinical Research Supports Ceflatonin(R) In Treatment Of Acute Myeloid Leukemia (AML) 3/23/2006
More...
|
Vion Pharmaceuticals (VION) Announces Plans To Conduct A Pivotal Phase II Trial Of Cloretazine(R) In Elderly Poor-Risk Acute Myelogenous Leukemia 1/31/2006
More...
|
Vion Pharmaceuticals (VION) Receives Orphan Drug Designation For Cloretazine(R) In Europe For Treatment Of Acute Myeloid Leukemia 1/23/2006
More...
|
St. Jude Children's Research Hospital Release: National Study Improves Outcome For Pediatric AML 12/14/2005
More...
|
Pharmion Corporation (PHRM) Release: Clinical Data On Vidaza(R) (Azacitidine for Injectable Suspension) In Higher-Risk MDS And AML Patients Presented At 47th Annual Meeting Of American Society of Hematology 12/12/2005
More...
|
Cephalon, Inc. (CEPH) Oncology Reports Clinical Response To CEP-701 Correlates With Targeted Inhibition Of FLT3 Mutation In Acute Myelogenous Leukemia 12/12/2005
More...
|
Seattle Genetics, Inc. (SGEN) Initiates SGN-33 Clinical Trial 11/17/2005
More...
|
GlaxoSmithKline (GSK) Announces Approval Of ARRANON(R) Injection 10/28/2005
More...
|
Xanthus Life Sciences Initiates A Phase 2 Study Of Xanafide In Combination With Ara-C For Treatment Of Secondary AML 10/20/2005
More...
|
SGX Pharmaceuticals, Inc. Receives Fast Track Designation For Troxatyl(TM) 10/19/2005
More...
|
Vion Pharmaceuticals (VION) Receives Fast Track Designation for Cloretazine(R) in Elderly Poor-Risk Acute Myelogenous Leukemia 10/17/2005
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Initiates Combination Phase I/II Trial Of MLN518 In Acute Myelogenous Leukemia 10/17/2005
More...
|
SGX Pharmaceuticals, Inc. Release: EMEA Grants Orphan Drug Designation To Troxatyl(TM) For The Treatment Of Acute Myeloid Leukemia 9/27/2005
More...
|
Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) Receives Not Approvable Letter From FDA For Tipifarnib Based On Phase II Data 7/1/2005
More...
|
Callisto Pharmaceuticals Receives Second Orphan Drug Designation On Annamycin With Granting Of Indication To Treat Acute Myeloid Leukemia 6/28/2005
More...
|
ChemGenex Pharmaceuticals Limited (CXS.AX) And Stragen Pharma S.A Create Alliance To Accelerate Clinical Development And Commercialization Of Ceflatonin(R) 6/28/2005
More...
|
Cephalon (CEPH) Announces Acquisition Of TRISENOX(R) From Cell Therapeutics, Inc. (CTIC); $70 Million Cash, Up to $100 Million 6/13/2005
More...
|
Nippon Shinyaku Co., Ltd. , Jeil-Kirin Pharmaceutical Conclude Licensing Agreement For TRISENOX Injection 5/23/2005
More...
|
Xanthus Life Sciences Presents At American Society of Clinical Oncology: Phase 1 Data Shows Significant Activity Of Amonafide In Combination With ara-C For Treatment Of Poor Risk AML 5/17/2005
More...
|
US FDA Panel Rejects Johnson & Johnson (JNJ) Leukemia Pill 5/6/2005
More...
|
The U.S. FDA Grants Orphan Drug Status To Lorus Therapeutics Inc.' (LRP) GTI-2040 In Acute Myeloid Leukemia 5/4/2005
More...
|
Antisoma PLC (ASM.L) Presents Promising AS1411 Data At TIDES Meeting 5/4/2005
More...
|
ImmunoGen, Inc. (IMGN) Announces Data Reported At American Association for Cancer Research On AVE9633 Anticancer Compound 4/20/2005
More...
|
ImmunoGen, Inc. (IMGN) Announces Achievement Of Milestone In Collaboration With Sanofi-Aventis (France) (SASY.PA) 3/17/2005
More...
|
Bioenvision (BIOV) To Report Important Clofarabine Clinical Update And To Host Conference Call On March 21, 2005 3/17/2005
More...
|
Maxim Pharmaceuticals, Inc. (MAXM) Release: Ceplene Receives Orphan Drug Designation In Europe For Acute Myeloid Leukemia 3/9/2005
More...
|
National Comprehensive Cancer Network (NCCN) Releases Acute Myeloid Leukemia And Chronic Myelogenous Leukemia Chapters Of The NCCN Drugs & Biologics Compendium 2/28/2005
More...
|
Vion Pharmaceuticals (VION) Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of CLORETAZINE(TM) (VNP40101M) In Relapsed AML 2/10/2005
More...
|
Maxim Pharmaceuticals, Inc. (MAXM) Realigns Corporate Objectives; Additional Phase 3 Trial Of Ceplene(TM); Reducing Workforce 2/8/2005
More...
|
Johnson and Johnson Pharmaceutical R&D (NJ) Completes Submission Of Tipifarnib NDA To FDA Continuous Marketing Application Pilot-1 Program 1/24/2005
More...
|
Cytoplasmic Location Of Shuttling Protein Often Seen With AML 1/20/2005
More...
|
Maxim Pharmaceuticals, Inc. (MAXM) Reports That Additional Phase 3 Trial Of Ceplene Therapy In The Treatment Of Acute Myeloid Leukemia Patients In Complete Remission Will Be Required By The FDA 1/18/2005
More...
|
Cell Therapeutics, Inc. (CTIC) Release: TRISENOX(R) Now Available To APL Patients In Japan After Nippon Shinyaku Co., Ltd. Launch 12/8/2004
More...
|
Bioenvision (BIOV) Release: Clofarabine Achieves High Response Rates In Acute Myeloid Leukaemia -AML-; Three Fold Increase In Response Rates Compared With Current Standard Of Care 12/6/2004
More...
|
Maxim Pharmaceuticals, Inc. (MAXM) Reports Data From Its Phase 3 Trial Of Ceplene In Acute Myeloid Leukemia Patients At American Society of Hematology (ASH) Annual Meeting 12/6/2004
More...
|
Genta Incorporated (GNTA) Release: Phase 2 Study Of Genasense(R) Plus Mylotarg(R) Yields Complete Remissions In Older Patients With Acute Myeloid Leukemia 12/6/2004
More...
|
Maxim Pharmaceuticals, Inc. (MAXM) To Host Conference Call; Review Of AML Data Presented At American Society of Hematology (ASH) To Be Provided 12/3/2004
More...
|
ILEX Oncology, Inc. (ILXO) Drug Helps One Leukemia, Not Another -US Panel 12/2/2004
More...
|
Vion Pharmaceuticals (VION) Receives Orphan Drug Designation For CLORETAZINE(TM) (VNP40101M) 10/26/2004
More...
|
Cell Therapeutics (CTIC) Release: Treatment Of Newly Diagnosed Acute Promyelocytic Leukemia With Arsenic Trioxide May Remove Need For Anthracycline Chemotherapy 10/4/2004
More...
|
ILEX Oncology's (ILXO) Clofarabine Scheduled For FDA Advisory Committee Review; ODAC To Review Pivotal Data For Pediatric Acute Leukemia 9/29/2004
More...
|
Juvaris BioTherapeutics Announces Collaboration With Penn State University For Acute Myelogenous Leukemia 9/28/2004
More...
|
Novartis (NVS) Release: Largest Study In Gastrointestinal Stromal Tumor Patients Shows Higher Dose Of Gleevec(R) Significantly Improves Progression-Free Survival 9/24/2004
More...
|
Cytogen Corporation (CYTO) Release: New Data Demonstrates Potential Role For QUADRAMET(TM) In Acute Myeloid Leukemia 9/20/2004
More...
|
ILEX Oncology (ILXO) Updates Clofarabine NDA With Encouraging Results; Additional Patient Data Resets FDA Action Date 8/25/2004
More...
|
New Clinical Data Enhances Bioenvision's (BIOV) Global Regulatory Strategy; Higher Response Rates Observed In New Cohort Of Patients With Pediatric Acute Leukemia 8/25/2004
More...
|
First Patients Enter Pivotal Phase II Study To Evaluate Bioenvision's (BIOV) Clofarabine In Adult Acute Leukemia 8/10/2004
More...
|
Structural GenomiX, Inc. Acquires Anti-Cancer Agent From Shire BioChem, Inc. 7/29/2004
More...
|
Perpetual AML Can Arise From Rare Leukemic Stem Cell 6/1/2004
More...
|
Bioenvision's (BIOV) Trial Of Clofarabine In Adult Acute Leukemia Exceeds Expectations; Study Closed Early To Expedite Enrollment In Pivotal Studies 5/19/2004
More...
|
Bioenvision (BIOV) Extends Exclusive Option To Market Clofarabine In Japan And Southeast Asia 5/18/2004
More...
|
Maxim Pharmaceuticals (MAXM) Announces Phase 3 Trial Of Ceplene In Acute Myeloid Leukemia Meets Primary Trial Endpoint; Stock Soars On Results 5/12/2004
More...
|
Gene Expression Profiling Yields Prognostic Information For AML Patients 4/14/2004
More...
|
Vion Pharmaceuticals (VION) Initiates Phase II Trial Of CLORETAZINE (VNP40101M) In Patients With Acute Myeloid Leukemia 3/29/2004
More...
|
Vion Pharmaceuticals (VION) Receives Fast Track Designation For CLORETAZINE(TM) (VNP40101M) In Relapsed Or Refractory Acute Myeloid Leukemia 3/8/2004
More...
|
Bioenvision (BIOV) Signs CRO Contract With Covance Inc. (CVD) 1/28/2004
More...
|
Cell Therapeutics' (CTIC) TRISENOX(R)-ATRA Therapy Produces High Complete Remission Rates In Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) 12/9/2003
More...
|
Cell Therapeutics' (CTIC) TRISENOX(R) Produces Durable Responses In Patients With Both High-Risk And Low-Risk Myelodysplasia 12/8/2003
More...
|
Cell Genesys, Inc. (CEGE) Reports Interim Clinical Data From Phase 2 Trial Of GVAX(R) Leukemia Vaccine 12/8/2003
More...
|
Genta Incorporated (GNTA) Release: Genasense(TM) Plus Chemotherapy Reported Active As Initial Treatment For Older Patients With Acute Myeloid Leukemia 12/8/2003
More...
|
Cancer Genetics Launches Revolutionary Weapon For The War On Cancer 12/5/2003
More...
|
Celgene's (CELG) Clinical Data On Alkeran(R) (Melphalan) In Hematological Cancers To Be Presented At The American Society of Hematology (ASH) 45th Annual Meeting 12/2/2003
More...
|